{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T21:55:55Z","timestamp":1780437355492,"version":"3.54.1"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s43440-025-00816-4","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T10:20:47Z","timestamp":1767608447000},"page":"405-422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["BET inhibitors in cardiovascular diseases: from atherosclerosis to heart failure"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5951-4864","authenticated-orcid":false,"given":"Moein","family":"Ala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izat","family":"Mohammad Khawajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Shamshiri Khamene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"816_CR1","doi-asserted-by":"publisher","first-page":"6495","DOI":"10.1002\/jcp.26497","volume":"233","author":"MG Daskalaki","year":"2018","unstructured":"Daskalaki MG, Tsatsanis C, Kampranis SC. Histone methylation and acetylation in macrophages as a mechanism for regulation of inflammatory responses. J Cell Physiol. 2018;233:6495\u2013507.","journal-title":"J Cell Physiol"},{"key":"816_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13046-019-1044-z","volume":"38","author":"P Fan","year":"2019","unstructured":"Fan P, Zhao J, Meng Z, Wu H, Wang B, Wu H, et al. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer. J Exp Clin Cancer Res. 2019;38:47.","journal-title":"J Exp Clin Cancer Res"},{"key":"816_CR3","doi-asserted-by":"crossref","unstructured":"Cochran AG, Conery AR, Sims RJ 3rd. Bromodomains: a new target class for drug development. Nat Rev Drug Discov. 2019;18:609\u201328.","DOI":"10.1038\/s41573-019-0030-7"},{"key":"816_CR4","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nature09589","volume":"468","author":"E Nicodeme","year":"2010","unstructured":"Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, Chung CW, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468:1119\u201323.","journal-title":"Nature"},{"key":"816_CR5","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1038\/nature09504","volume":"468","author":"P Filippakopoulos","year":"2010","unstructured":"Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, et al. Selective Inhibition of BET bromodomains. Nature. 2010;468:1067\u201373.","journal-title":"Nature"},{"key":"816_CR6","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/genes3020320","volume":"3","author":"GA Josling","year":"2012","unstructured":"Josling GA, Selvarajah SA, Petter M, Duffy MF. The role of bromodomain proteins in regulating gene expression. Genes (Basel). 2012;3:320\u201343.","journal-title":"Genes (Basel)"},{"key":"816_CR7","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1021\/jm501963e","volume":"58","author":"L Drouin","year":"2015","unstructured":"Drouin L, McGrath S, Vidler LR, Chaikuad A, Monteiro O, Tallant C, et al. Structure enabled design of BAZ2-ICR, a chemical probe targeting the bromodomains of BAZ2A and BAZ2B. J Med Chem. 2015;58:2553\u20139.","journal-title":"J Med Chem"},{"key":"816_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.molcel.2005.06.027","volume":"19","author":"MK Jang","year":"2005","unstructured":"Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005;19:523\u201334.","journal-title":"Mol Cell"},{"key":"816_CR9","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/20974","volume":"399","author":"C Dhalluin","year":"1999","unstructured":"Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. Structure and ligand of a histone acetyltransferase bromodomain. Nature. 1999;399:491\u20136.","journal-title":"Nature"},{"key":"816_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cell.2012.02.013","volume":"149","author":"P Filippakopoulos","year":"2012","unstructured":"Filippakopoulos P, Picaud S, Mangos M, Keates T, Lambert JP, Barsyte-Lovejoy D, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149:214\u201331.","journal-title":"Cell"},{"key":"816_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41392-020-00384-4","volume":"6","author":"N Wang","year":"2021","unstructured":"Wang N, Wu R, Tang D, Kang R. The BET family in immunity and disease. Signal Transduct Target Ther. 2021;6:23.","journal-title":"Signal Transduct Target Ther"},{"key":"816_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/cmdc.201300434","volume":"9","author":"D Gallenkamp","year":"2014","unstructured":"Gallenkamp D, Gelato KA, Haendler B, Weinmann H. Bromodomains and their Pharmacological inhibitors. ChemMedChem. 2014;9:438\u201364.","journal-title":"ChemMedChem"},{"key":"816_CR13","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41416-022-01815-5","volume":"127","author":"U Tontsch-Grunt","year":"2022","unstructured":"Tontsch-Grunt U, Traexler PE, Baum A, Musa H, Marzin K, Wang S, et al. Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic. Br J Cancer. 2022;127:577\u201386.","journal-title":"Br J Cancer"},{"key":"816_CR14","doi-asserted-by":"publisher","first-page":"621093","DOI":"10.3389\/fphar.2020.621093","volume":"11","author":"Y Sun","year":"2020","unstructured":"Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Safety and efficacy of bromodomain and Extra-Terminal inhibitors for the treatment of hematological malignancies and solid tumors: A systematic study of clinical trials. Front Pharmacol. 2020;11:621093.","journal-title":"Front Pharmacol"},{"key":"816_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40256-017-0250-3","volume":"18","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Ray KK, Johansson JO, Gordon A, Sweeney M, Halliday C, et al. Selective BET protein Inhibition with apabetalone and cardiovascular events: A pooled analysis of trials in patients with coronary artery disease. Am J Cardiovasc Drugs. 2018;18:109\u201315.","journal-title":"Am J Cardiovasc Drugs"},{"key":"816_CR16","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.4049\/jimmunol.1202838","volume":"190","author":"AC Belkina","year":"2013","unstructured":"Belkina AC, Nikolajczyk BS, Denis GV. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol. 2013;190:3670\u20138.","journal-title":"J Immunol"},{"key":"816_CR17","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1177\/0022034514534261","volume":"93","author":"S Meng","year":"2014","unstructured":"Meng S, Zhang L, Tang Y, Tu Q, Zheng L, Yu L, et al. BET inhibitor JQ1 blocks inflammation and bone destruction. J Dent Res. 2014;93:657\u201362.","journal-title":"J Dent Res"},{"key":"816_CR18","doi-asserted-by":"publisher","first-page":"H294","DOI":"10.1152\/ajpheart.00438.2024","volume":"328","author":"KB Schuetze","year":"2025","unstructured":"Schuetze KB, Stratton MS, Bagchi RA, Hobby ARH, Felisbino MB, Rubino M, et al. BRD4 Inhibition rewires cardiac macrophages toward a protective phenotype marked by low MHC class II expression. Am J Physiol Heart Circ Physiol. 2025;328:H294\u2013309.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"816_CR19","doi-asserted-by":"publisher","first-page":"16932","DOI":"10.1038\/srep16932","volume":"5","author":"A Das","year":"2015","unstructured":"Das A, Chai JC, Yang CS, Lee YS, Das ND, Jung KH, et al. Dual transcriptome sequencing reveals resistance of TLR4 ligand-activated bone marrow-derived macrophages to inflammation mediated by the BET inhibitor JQ1. Sci Rep. 2015;5:16932.","journal-title":"Sci Rep"},{"key":"816_CR20","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/jcb.29556","volume":"121","author":"M Luo","year":"2020","unstructured":"Luo M, Yan D, Sun Q, Tao J, Xu L, Sun H, et al. Ginsenoside Rg1 attenuates cardiomyocyte apoptosis and inflammation via the TLR4\/NF-kB\/NLRP3 pathway. J Cell Biochem. 2020;121:2994\u20133004.","journal-title":"J Cell Biochem"},{"key":"816_CR21","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1016\/j.celrep.2016.08.032","volume":"16","author":"H Zhu","year":"2016","unstructured":"Zhu H, Bengsch F, Svoronos N, Rutkowski MR, Bitler BG, Allegrezza MJ, et al. BET bromodomain Inhibition promotes Anti-tumor immunity by suppressing PD-L1 expression. Cell Rep. 2016;16:2829\u201337.","journal-title":"Cell Rep"},{"key":"816_CR22","doi-asserted-by":"publisher","first-page":"e95051","DOI":"10.1371\/journal.pone.0095051","volume":"9","author":"YM Khan","year":"2014","unstructured":"Khan YM, Kirkham P, Barnes PJ, Adcock IM. Brd4 is essential for IL-1\u03b2-induced inflammation in human airway epithelial cells. PLoS ONE. 2014;9:e95051.","journal-title":"PLoS ONE"},{"key":"816_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41573-018-0008-x","volume":"18","author":"A Cuadrado","year":"2019","unstructured":"Cuadrado A, Rojo AI, Wells G, Hayes JD, Cousin SP, Rumsey WL, et al. Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discovery. 2019;18:295\u2013317.","journal-title":"Nat Rev Drug Discovery"},{"key":"816_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.biochi.2019.07.012","volume":"165","author":"H Zuo","year":"2019","unstructured":"Zuo H, Wang S, Feng J, Liu X. BRD4 contributes to high-glucose-induced podocyte injury by modulating Keap1\/Nrf2\/ARE signaling. Biochimie. 2019;165:100\u20137.","journal-title":"Biochimie"},{"key":"816_CR25","doi-asserted-by":"publisher","first-page":"8197","DOI":"10.1007\/s11033-022-07377-2","volume":"49","author":"W Li","year":"2022","unstructured":"Li W, Shen X, Feng S, Liu Y, Zhao H, Zhou G, et al. BRD4 Inhibition by JQ1 protects against LPS-induced cardiac dysfunction by inhibiting activation of NLRP3 inflammasomes. Mol Biol Rep. 2022;49:8197\u2013207.","journal-title":"Mol Biol Rep"},{"key":"816_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41586-021-03478-3","volume":"593","author":"S Xia","year":"2021","unstructured":"Xia S, Zhang Z, Magupalli VG, Pablo JL, Dong Y, Vora SM, et al. Gasdermin D pore structure reveals Preferential release of mature interleukin-1. Nature. 2021;593:607\u201311.","journal-title":"Nature"},{"key":"816_CR27","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41392-021-00507-5","volume":"6","author":"P Yu","year":"2021","unstructured":"Yu P, Zhang X, Liu N, Tang L, Peng C, Chen X. Pyroptosis: mechanisms and diseases. Signal Transduct Target Ther. 2021;6:128.","journal-title":"Signal Transduct Target Ther"},{"key":"816_CR28","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.phrs.2012.10.010","volume":"67","author":"J Xie","year":"2013","unstructured":"Xie J, Zhang X, Zhang L. Negative regulation of inflammation by SIRT1. Pharmacol Res. 2013;67:60\u20137.","journal-title":"Pharmacol Res"},{"key":"816_CR29","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1080\/15384101.2020.1743911","volume":"19","author":"Z Zheng","year":"2020","unstructured":"Zheng Z, Bian Y, Zhang Y, Ren G, Li G. Metformin activates AMPK\/SIRT1\/NF-\u03baB pathway and induces mitochondrial dysfunction to drive caspase3\/GSDME-mediated cancer cell pyroptosis. Cell Cycle. 2020;19:1089\u2013104.","journal-title":"Cell Cycle"},{"key":"816_CR30","doi-asserted-by":"publisher","first-page":"893","DOI":"10.3892\/ol.2020.11635","volume":"20","author":"Z Chen","year":"2020","unstructured":"Chen Z, He M, Chen J, Li C, Zhang Q. Long non-coding RNA SNHG7 inhibits NLRP3-dependent pyroptosis by targeting the miR-34a\/SIRT1 axis in liver cancer. Oncol Lett. 2020;20:893\u2013901.","journal-title":"Oncol Lett"},{"key":"816_CR31","doi-asserted-by":"crossref","unstructured":"Mills RJ, Humphrey SJ, Fortuna PRJ, Lor M, Foster SR, Quaife-Ryan GA, et al. BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. Cell. 2021;184:2167-82.e22.","DOI":"10.1016\/j.cell.2021.03.026"},{"key":"816_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fphar.2017.00186","volume":"8","author":"L Fang","year":"2017","unstructured":"Fang L, Murphy AJ, Dart AM. A clinical perspective of Anti-Fibrotic therapies for cardiovascular disease. Front Pharmacol. 2017;8:186.","journal-title":"Front Pharmacol"},{"key":"816_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1161\/CIRCEP.114.001610","volume":"7","author":"I Agarwal","year":"2014","unstructured":"Agarwal I, Glazer NL, Barasch E, Biggs ML, Djousse L, Fitzpatrick AL, et al. Fibrosis-related biomarkers and incident cardiovascular disease in older adults: the cardiovascular health study. Circ Arrhythm Electrophysiol. 2014;7:583\u20139.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"816_CR34","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.kint.2021.04.016","volume":"100","author":"C Ponticelli","year":"2021","unstructured":"Ponticelli C, Campise MR. The inflammatory state is a risk factor for cardiovascular disease and graft fibrosis in kidney transplantation. Kidney Int. 2021;100:536\u201345.","journal-title":"Kidney Int"},{"key":"816_CR35","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.yjmcc.2014.05.002","volume":"74","author":"SM Haldar","year":"2014","unstructured":"Haldar SM, McKinsey TA. BET-ting on chromatin-based therapeutics for heart failure. J Mol Cell Cardiol. 2014;74:98\u2013102.","journal-title":"J Mol Cell Cardiol"},{"key":"816_CR36","doi-asserted-by":"publisher","first-page":"102057","DOI":"10.1016\/j.pupt.2021.102057","volume":"70","author":"S Kaneshita","year":"2021","unstructured":"Kaneshita S, Kida T, Yoshioka M, Nishioka K, Raje M, Sakashita A, et al. CG223, a novel BET inhibitor, exerts TGF-\u03b21-mediated antifibrotic effects in a murine model of bleomycin-induced pulmonary fibrosis. Pulm Pharmacol Ther. 2021;70:102057.","journal-title":"Pulm Pharmacol Ther"},{"key":"816_CR37","doi-asserted-by":"publisher","first-page":"69291","DOI":"10.18632\/oncotarget.12498","volume":"7","author":"C Xiong","year":"2016","unstructured":"Xiong C, Masucci MV, Zhou X, Liu N, Zang X, Tolbert E, et al. Pharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosis. Oncotarget. 2016;7:69291\u2013308.","journal-title":"Oncotarget"},{"key":"816_CR38","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1161\/01.RES.0000142315.88477.42","volume":"95","author":"FG Spinale","year":"2004","unstructured":"Spinale FG. Cell-matrix signaling and thrombospondin: another link to myocardial matrix remodeling. Circ Res. 2004;95:446\u20138.","journal-title":"Circ Res"},{"key":"816_CR39","doi-asserted-by":"crossref","unstructured":"Vichaikul S, Gurrea-Rubio M, Amin MA, Campbell PL, Wu Q, Mattichak MN et al. Inhibition of bromodomain extraterminal histone readers alleviates skin fibrosis in experimental models of scleroderma. JCI Insight. 2022;7.","DOI":"10.1172\/jci.insight.150871"},{"key":"816_CR40","doi-asserted-by":"publisher","first-page":"ehae666","DOI":"10.1093\/eurheartj\/ehae666.3756","volume":"45","author":"S Costantino","year":"2024","unstructured":"Costantino S, Gorica E, Mohammed S, Telesca M, Mongelli A, Herwig M, et al. The BET inhibitor apabetalone protects against heart failure with preserved ejection fraction by suppressing myocardial inflammation. Eur Heart J. 2024;45:ehae666.","journal-title":"Eur Heart J"},{"key":"816_CR41","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.hrthm.2019.01.013","volume":"16","author":"Z Liu","year":"2019","unstructured":"Liu Z, Finet JE, Wolfram JA, Anderson ME, Ai X, Donahue JK. Calcium\/calmodulin-dependent protein kinase II causes atrial structural remodeling associated with atrial fibrillation and heart failure. Heart Rhythm. 2019;16:1080\u20138.","journal-title":"Heart Rhythm"},{"key":"816_CR42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2217\/epi.13.73","volume":"6","author":"Z Wang","year":"2014","unstructured":"Wang Z, Qin G, Zhao TC. HDAC4: mechanism of regulation and biological functions. Epigenomics. 2014;6:139\u201350.","journal-title":"Epigenomics"},{"key":"816_CR43","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.apsb.2021.07.018","volume":"12","author":"Z He","year":"2022","unstructured":"He Z, Jiao H, An Q, Zhang X, Zengyangzong D, Xu J, et al. Discovery of novel 4-phenylquinazoline-based BRD4 inhibitors for cardiac fibrosis. Acta Pharm Sin B. 2022;12:291\u2013307.","journal-title":"Acta Pharm Sin B"},{"key":"816_CR44","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1161\/hh2401.100742","volume":"89","author":"G Xiao","year":"2001","unstructured":"Xiao G, Mao S, Baumgarten G, Serrano J, Jordan MC, Roos KP, et al. Inducible activation of c-Myc in adult myocardium in vivo provokes cardiac myocyte hypertrophy and reactivation of DNA synthesis. Circ Res. 2001;89:1122\u20139.","journal-title":"Circ Res"},{"key":"816_CR45","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1161\/CIRCRESAHA.119.315125","volume":"125","author":"MS Stratton","year":"2019","unstructured":"Stratton MS, Bagchi RA, Felisbino MB, Hirsch RA, Smith HE, Riching AS, et al. Dynamic chromatin targeting of BRD4 stimulates cardiac fibroblast activation. Circ Res. 2019;125:662\u201377.","journal-title":"Circ Res"},{"key":"816_CR46","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1093\/emboj\/cdf366","volume":"21","author":"L Yu","year":"2002","unstructured":"Yu L, H\u00e9bert MC, Zhang YE. TGF-beta receptor-activated p38 MAP kinase mediates Smad-independent TGF-beta responses. Embo J. 2002;21:3749\u201359.","journal-title":"Embo J"},{"key":"816_CR47","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1016\/j.lfs.2003.09.075","volume":"74","author":"S Donnini","year":"2004","unstructured":"Donnini S, Morbidelli L, Taraboletti G, Ziche M. ERK1-2 and p38 MAPK regulate MMP\/TIMP balance and function in response to thrombospondin-1 fragments in the microvascular endothelium. Life Sci. 2004;74:2975\u201385.","journal-title":"Life Sci"},{"key":"816_CR48","unstructured":"Stratton M, Francois A, Bermeo-Blanco O, Canella A, Marcho L, McGrail E, et al. Abstract MP259: the role of Sertad4 in pathological cardiac remodeling. Suppl_1 ed: Am Heart Assoc. p. AMP259-AMP."},{"key":"816_CR49","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.arcmed.2015.06.006","volume":"46","author":"S Barquera","year":"2015","unstructured":"Barquera S, Pedroza-Tob\u00edas A, Medina C, Hern\u00e1ndez-Barrera L, Bibbins-Domingo K, Lozano R, et al. Global overview of the epidemiology of atherosclerotic cardiovascular disease. Arch Med Res. 2015;46:328\u201338.","journal-title":"Arch Med Res"},{"key":"816_CR50","doi-asserted-by":"crossref","unstructured":"Ziegler T, Abdel Rahman F, Jurisch V, Kupatt C. Atherosclerosis and the capillary Network; pathophysiology and potential therapeutic strategies. Cells. 2019;9.","DOI":"10.3390\/cells9010050"},{"key":"816_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13148-019-0696-z","volume":"11","author":"LM Tsujikawa","year":"2019","unstructured":"Tsujikawa LM, Fu L, Das S, Halliday C, Rakai BD, Stotz SC, et al. Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism. Clin Epigenetics. 2019;11:1\u201321.","journal-title":"Clin Epigenetics"},{"key":"816_CR52","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2022.11.015","volume":"364","author":"S Wasiak","year":"2023","unstructured":"Wasiak S, Tsujikawa LM, Daze E, Gilham D, Stotz SC, Rakai BD, et al. Epigenetic BET reader inhibitor apabetalone (RVX-208) counters Proinflammatory aortic gene expression in a diet induced obesity mouse model and in human endothelial cells. Atherosclerosis. 2023;364:10\u20139.","journal-title":"Atherosclerosis"},{"key":"816_CR53","doi-asserted-by":"publisher","first-page":"ehae666","DOI":"10.1093\/eurheartj\/ehae666.3647","volume":"45","author":"S Mohammed","year":"2024","unstructured":"Mohammed S, Telesca M, Gorica E, Panteloglou G, Mongelli A, Ruschitzka F, et al. The BET protein inhibitor apabetalone (RVX-208) prevents doxorubicin-induced endothelial senescence. Eur Heart J. 2024;45:ehae666.","journal-title":"Eur Heart J"},{"key":"816_CR54","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0735-1097(19)32669-5","volume":"73","author":"L Tsujikawa","year":"2019","unstructured":"Tsujikawa L, Fu L, Das S, Rakai BD, Sarsons CD, Halliday C, et al. Apabetalone, an epigenetic BET inhibitor in a phase 3 trial, inhibits vascular inflammation and cellular adhesion leading to beneficial outcomes in CVD patients. J Am Coll Cardiol. 2019;73:2063.","journal-title":"J Am Coll Cardiol"},{"key":"816_CR55","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s12265-017-9755-z","volume":"10","author":"S Wasiak","year":"2017","unstructured":"Wasiak S, Gilham D, Tsujikawa LM, Halliday C, Calosing C, Jahagirdar R, et al. Downregulation of the complement cascade in vitro, in mice and in patients with cardiovascular disease by the BET protein inhibitor apabetalone (RVX-208). J Cardiovasc Transl Res. 2017;10:337\u201347.","journal-title":"J Cardiovasc Transl Res"},{"key":"816_CR56","doi-asserted-by":"publisher","first-page":"9240","DOI":"10.18632\/aging.103200","volume":"12","author":"H Wang","year":"2020","unstructured":"Wang H, Fu H, Zhu R, Wu X, Ji X, Li X, et al. BRD4 contributes to LPS-induced macrophage senescence and promotes progression of atherosclerosis-associated lipid uptake. Aging. 2020;12:9240\u201359.","journal-title":"Aging"},{"key":"816_CR57","doi-asserted-by":"crossref","unstructured":"Tonini C, Colardo M, Colella B, Di Bartolomeo S, Berardinelli F, Caretti G et al. Inhibition of bromodomain and extraterminal domain (BET) proteins by JQ1 unravels a novel epigenetic modulation to control lipid homeostasis. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21041297"},{"key":"816_CR58","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.atherosclerosis.2014.06.008","volume":"236","author":"R Jahagirdar","year":"2014","unstructured":"Jahagirdar R, Zhang H, Azhar S, Tobin J, Attwell S, Yu R, et al. A novel BET bromodomain inhibitor, RVX-208, shows reduction of atherosclerosis in hyperlipidemic ApoE deficient mice. Atherosclerosis. 2014;236:91\u2013100.","journal-title":"Atherosclerosis"},{"key":"816_CR59","doi-asserted-by":"publisher","first-page":"4196482","DOI":"10.1155\/2020\/4196482","volume":"2020","author":"Y Wu","year":"2020","unstructured":"Wu Y, Zhang M, Xu C, Chai D, Peng F, Lin J. Anti-Diabetic atherosclerosis by inhibiting high Glucose-Induced vascular smooth muscle cell proliferation via Pin1\/BRD4 pathway. Oxid Med Cell Longev. 2020;2020:4196482.","journal-title":"Oxid Med Cell Longev"},{"key":"816_CR60","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1093\/cvr\/cvaa121","volume":"117","author":"J Dutzmann","year":"2021","unstructured":"Dutzmann J, Haertl\u00e9 M, Daniel JM, Kloss F, Musmann RJ, Kalies K, et al. BET bromodomain-containing epigenetic reader proteins regulate vascular smooth muscle cell proliferation and Neointima formation. Cardiovasc Res. 2021;117:850\u201362.","journal-title":"Cardiovasc Res"},{"key":"816_CR61","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1089\/ars.2021.0127","volume":"36","author":"SA Mohammed","year":"2022","unstructured":"Mohammed SA, Albiero M, Ambrosini S, Gorica E, Karsai G, Caravaggi CM, et al. The BET protein inhibitor apabetalone rescues Diabetes-Induced impairment of angiogenic response by epigenetic regulation of Thrombospondin-1. Antioxid Redox Signal. 2022;36:667\u201384.","journal-title":"Antioxid Redox Signal"},{"key":"816_CR62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.atherosclerosis.2019.09.002","volume":"290","author":"M Haarhaus","year":"2019","unstructured":"Haarhaus M, Ray KK, Nicholls SJ, Schwartz GG, Kulikowski E, Johansson JO, et al. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. Atherosclerosis. 2019;290:59\u201365.","journal-title":"Atherosclerosis"},{"key":"816_CR63","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2018.11.002","volume":"280","author":"D Gilham","year":"2019","unstructured":"Gilham D, Tsujikawa LM, Sarsons CD, Halliday C, Wasiak S, Stotz SC, et al. Apabetalone downregulates factors and pathways associated with vascular calcification. Atherosclerosis. 2019;280:75\u201384.","journal-title":"Atherosclerosis"},{"key":"816_CR64","doi-asserted-by":"publisher","first-page":"ehae666","DOI":"10.1093\/eurheartj\/ehae666.3813","volume":"45","author":"E Kulikowski","year":"2024","unstructured":"Kulikowski E, Wasiak S, Gilham D, Fu L, Tsujikawa L, Carestia A, et al. Epigenetic BET inhibitor apabetalone counters inflammatory and fibrotic processes in activated cardiac fibroblasts providing insight into reduced hospitalizations for heart failure in BETonMACE trial. Eur Heart J. 2024;45:ehae666.","journal-title":"Eur Heart J"},{"key":"816_CR65","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/j.jash.2018.11.004","volume":"12","author":"YM Yang","year":"2018","unstructured":"Yang YM, Shi RH, Xu CX, Li L. BRD4 expression in patients with essential hypertension and its effect on blood pressure in spontaneously hypertensive rats. J Am Soc Hypertens. 2018;12:e107\u201317.","journal-title":"J Am Soc Hypertens"},{"key":"816_CR66","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1161\/01.HYP.0000158262.11935.d0","volume":"45","author":"DM Pollock","year":"2005","unstructured":"Pollock DM. Endothelin, angiotensin, and oxidative stress in hypertension. Hypertension. 2005;45:477\u201380.","journal-title":"Hypertension"},{"key":"816_CR67","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.niox.2014.09.001","volume":"42","author":"O Boonla","year":"2014","unstructured":"Boonla O, Kukongviriyapan U, Pakdeechote P, Kukongviriyapan V, Pannangpetch P, Prachaney P, et al. Curcumin improves endothelial dysfunction and vascular remodeling in 2K-1\u00a0C hypertensive rats by Raising nitric oxide availability and reducing oxidative stress. Nitric Oxide. 2014;42:44\u201353.","journal-title":"Nitric Oxide"},{"key":"816_CR68","doi-asserted-by":"publisher","first-page":"e24266","DOI":"10.1371\/journal.pone.0024266","volume":"6","author":"W Niu","year":"2011","unstructured":"Niu W, Qi Y. An updated meta-analysis of endothelial nitric oxide synthase gene: three well-characterized polymorphisms with hypertension. PLoS ONE. 2011;6:e24266.","journal-title":"PLoS ONE"},{"key":"816_CR69","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.ijcard.2016.08.238","volume":"223","author":"Q Duan","year":"2016","unstructured":"Duan Q, Mao X, Liao C, Zhou H, Sun Z, Deng X, et al. Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE(-\/-) mice. Int J Cardiol. 2016;223:428\u201332.","journal-title":"Int J Cardiol"},{"key":"816_CR70","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3892\/etm.2015.2789","volume":"10","author":"Y Sun","year":"2015","unstructured":"Sun Y, Huang J, Song K. BET protein Inhibition mitigates acute myocardial infarction damage in rats via the TLR4\/TRAF6\/NF-\u03baB pathway. Exp Ther Med. 2015;10:2319\u201324.","journal-title":"Exp Ther Med"},{"key":"816_CR71","doi-asserted-by":"crossref","unstructured":"Sun Y, Xie Y, Du L, Sun J, Liu Z. Inhibition of BRD4 attenuates cardiomyocyte apoptosis via NF-\u03baB pathway in a rat model of myocardial infarction. Cardiovasc Ther. 2018;36.","DOI":"10.1111\/1755-5922.12320"},{"key":"816_CR72","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/FJC.0000000000001138","volume":"78","author":"H Wei","year":"2021","unstructured":"Wei H, Xue Q, Sun L, Lv J. BRD4 Inhibition protects against myocardial Ischemia\/Reperfusion injury by suppressing inflammation and oxidative stress through the PI3K\/AKT signaling pathway. J Cardiovasc Pharmacol. 2021;78:839\u201346.","journal-title":"J Cardiovasc Pharmacol"},{"key":"816_CR73","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/cbf.3536","volume":"38","author":"J Huang","year":"2020","unstructured":"Huang J, Jiang R, Chu X, Wang F, Sun X, Wang Y, et al. Overexpression of microRNA-23a-5p induces myocardial infarction by promoting cardiomyocyte apoptosis through inhibited of PI3K\/AKT signalling pathway. Cell Biochem Funct. 2020;38:1047\u201355.","journal-title":"Cell Biochem Funct"},{"key":"816_CR74","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10020-020-00241-8","volume":"26","author":"Q Feng","year":"2020","unstructured":"Feng Q, Li X, Qin X, Yu C, Jin Y, Qian X. PTEN inhibitor improves vascular remodeling and cardiac function after myocardial infarction through PI3k\/Akt\/VEGF signaling pathway. Mol Med. 2020;26:111.","journal-title":"Mol Med"},{"key":"816_CR75","doi-asserted-by":"publisher","first-page":"10756","DOI":"10.21037\/apm-21-2433","volume":"10","author":"X Chi","year":"2021","unstructured":"Chi X, Shan L, Hu Y, Zhang Y, Mao Y, Wang X. Bromodomain-containing protein 7 contributes to myocardial infarction-induced myocardial injury through activating Wnt\/\u03b2-catenin signaling. Ann Palliat Med. 2021;10:10756\u201367.","journal-title":"Ann Palliat Med"},{"key":"816_CR76","doi-asserted-by":"publisher","first-page":"154293","DOI":"10.1016\/j.phymed.2022.154293","volume":"104","author":"J He","year":"2022","unstructured":"He J, Wo D, Ma E, Wang Q, Chen J, Gao Q, et al. Huoxin pill prevents excessive inflammation and cardiac dysfunction following myocardial infarction by inhibiting adverse Wnt\/\u03b2\u2013catenin signaling activation. Phytomedicine. 2022;104:154293.","journal-title":"Phytomedicine"},{"key":"816_CR77","doi-asserted-by":"crossref","unstructured":"Bastakoty D, Saraswati S, Joshi P, Atkinson J, Feoktistov I, Liu J et al. Temporary, systemic Inhibition of the WNT\/\u03b2-Catenin pathway promotes regenerative cardiac repair following myocardial infarct. Cell Stem Cells Regen Med. 2016;2.","DOI":"10.16966\/2472-6990.111"},{"key":"816_CR78","doi-asserted-by":"crossref","unstructured":"Reid S, Fine N, Bhosle VK, Zhou J, John R, Glogauer M et al. Inhibition of BRD4 reduces neutrophil activation and adhesion to the vascular endothelium following ischemia reperfusion injury. Int J Mol Sci. 2020;21.","DOI":"10.3390\/ijms21249620"},{"key":"816_CR79","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1007\/s12035-021-02369-y","volume":"58","author":"W Zheng","year":"2021","unstructured":"Zheng W, Xie Q, Zhang Z, Li J, Fang L, Li W. Inhibited HDAC3 or elevated MicroRNA-494-3p plays a protective role in myocardial Ischemia-Reperfusion injury via suppression of BRD4. Mol Neurobiol. 2021;58:4268\u201379.","journal-title":"Mol Neurobiol"},{"key":"816_CR80","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/S0140-6736(14)60107-0","volume":"383","author":"G Heusch","year":"2014","unstructured":"Heusch G, Libby P, Gersh B, Yellon D, B\u00f6hm M, Lopaschuk G, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014;383:1933\u201343.","journal-title":"Lancet"},{"key":"816_CR81","doi-asserted-by":"crossref","unstructured":"Duan Q, McMahon S, Anand P, Shah H, Thomas S, Salunga HT, et al. BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. Sci Transl Med. 2017;9.","DOI":"10.1126\/scitranslmed.aah5084"},{"key":"816_CR82","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.yjmcc.2013.07.017","volume":"63","author":"JI Spiltoir","year":"2013","unstructured":"Spiltoir JI, Stratton MS, Cavasin MA, Demos-Davies K, Reid BG, Qi J, et al. BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. J Mol Cell Cardiol. 2013;63:175\u20139.","journal-title":"J Mol Cell Cardiol"},{"key":"816_CR83","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.cell.2013.07.013","volume":"154","author":"P Anand","year":"2013","unstructured":"Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell. 2013;154:569\u201382.","journal-title":"Cell"},{"key":"816_CR84","doi-asserted-by":"publisher","first-page":"109368","DOI":"10.1016\/j.biopha.2019.109368","volume":"121","author":"W Zhu","year":"2020","unstructured":"Zhu W, Wu RD, Lv YG, Liu YM, Huang H, Xu JQ. BRD4 blockage alleviates pathological cardiac hypertrophy through the suppression of fibrosis and inflammation via reducing ROS generation. Biomed Pharmacother. 2020;121:109368.","journal-title":"Biomed Pharmacother"},{"key":"816_CR85","doi-asserted-by":"publisher","first-page":"1484736","DOI":"10.1155\/2019\/1484736","volume":"2019","author":"CJW Stock","year":"2019","unstructured":"Stock CJW, Michaeloudes C, Leoni P, Durham AL, Mumby S, Wells AU, et al. Bromodomain and extraterminal (BET) protein Inhibition restores redox balance and inhibits myofibroblast activation. Biomed Res Int. 2019;2019:1484736.","journal-title":"Biomed Res Int"},{"key":"816_CR86","doi-asserted-by":"crossref","unstructured":"Martin RD, Sun Y, MacKinnon S, Cuccia L, Pag\u00e9 V, H\u00e9bert TE, et al. Differential activation of P-TEFb complexes in the development of cardiomyocyte hypertrophy following activation of distinct G Protein-Coupled receptors. Mol Cell Biol. 2020;40.","DOI":"10.1128\/MCB.00048-20"},{"key":"816_CR87","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1172\/JCI135922","volume":"130","author":"G Auguste","year":"2020","unstructured":"Auguste G, Rouhi L, Matkovich SJ, Coarfa C, Robertson MJ, Czernuszewicz G, et al. BET bromodomain Inhibition attenuates cardiac phenotype in myocyte-specific lamin A\/C-deficient mice. J Clin Invest. 2020;130:4740\u201358.","journal-title":"J Clin Invest"},{"key":"816_CR88","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1161\/01.RES.0000244015.10655.3f","volume":"99","author":"R Cui","year":"2006","unstructured":"Cui R, Tieu B, Recinos A, Tilton RG, Brasier AR. RhoA mediates angiotensin II-induced phospho-Ser536 nuclear factor kappaB\/RelA subunit exchange on the interleukin-6 promoter in VSMCs. Circ Res. 2006;99:723\u201330.","journal-title":"Circ Res"},{"key":"816_CR89","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1002\/ijc.33989","volume":"151","author":"CS Liu","year":"2022","unstructured":"Liu CS, Rioja I, Bakr A, Veldwijk MR, Sperk E, Herskind C, et al. Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses. Int J Cancer. 2022;151:275\u201386.","journal-title":"Int J Cancer"},{"key":"816_CR90","doi-asserted-by":"crossref","unstructured":"Lin Z, Li Z, Guo Z, Cao Y, Li J, Liu P, et al. Epigenetic reader bromodomain containing protein 2 facilitates pathological cardiac hypertrophy via regulating the expression of citrate cycle genes. Front Pharmacol. 2022;13.","DOI":"10.3389\/fphar.2022.887991"},{"key":"816_CR91","doi-asserted-by":"publisher","first-page":"154915","DOI":"10.1016\/j.metabol.2021.154915","volume":"125","author":"M Bull\u00f3","year":"2021","unstructured":"Bull\u00f3 M, Papandreou C, Garc\u00eda-Gavil\u00e1n J, Ruiz-Canela M, Li J, Guasch-Ferr\u00e9 M, et al. Tricarboxylic acid cycle related-metabolites and risk of atrial fibrillation and heart failure. Metabolism. 2021;125:154915.","journal-title":"Metabolism"},{"key":"816_CR92","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/j.celrep.2016.06.074","volume":"16","author":"MS Stratton","year":"2016","unstructured":"Stratton MS, Lin CY, Anand P, Tatman PD, Ferguson BS, Wickers ST, et al. Signal-dependent recruitment of BRD4 to cardiomyocyte super-enhancers is suppressed by a MicroRNA. Cell Rep. 2016;16:1366\u201378.","journal-title":"Cell Rep"},{"key":"816_CR93","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-020-01199-x","volume":"20","author":"SJ Nicholls","year":"2021","unstructured":"Nicholls SJ, Schwartz GG, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, et al. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovasc Diabetol. 2021;20:1\u20139.","journal-title":"Cardiovasc Diabetol"},{"key":"816_CR94","doi-asserted-by":"publisher","first-page":"100372","DOI":"10.1016\/j.ajpc.2022.100372","volume":"11","author":"PP Toth","year":"2022","unstructured":"Toth PP, Schwartz GG, Nicholls SJ, Khan A, Szarek M, Ginsberg HN, et al. Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease. Am J Prev Cardiol. 2022;11:100372.","journal-title":"Am J Prev Cardiol"},{"key":"816_CR95","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2215\/CJN.16751020","volume":"16","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K, Schwartz GG, Nicholls SJ, Buhr KA, Ginsberg HN, Johansson JO, et al. Effect of apabetalone on cardiovascular events in diabetes, CKD, and recent acute coronary syndrome: results from the BETonMACE randomized controlled trial. Clin J Am Soc Nephrol. 2021;16:705\u201316.","journal-title":"Clin J Am Soc Nephrol"},{"key":"816_CR96","doi-asserted-by":"crossref","unstructured":"Lan NSH, Massam BD, Kulkarni SS, Lang CC. Pulmonary arterial hypertension: pathophysiology and treatment. Diseases. 2018;6.","DOI":"10.3390\/diseases6020038"},{"key":"816_CR97","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/resp.12872","volume":"22","author":"S Mumby","year":"2017","unstructured":"Mumby S, Gambaryan N, Meng C, Perros F, Humbert M, Wort SJ, et al. Bromodomain and extra-terminal protein mimic JQ1 decreases inflammation in human vascular endothelial cells: implications for pulmonary arterial hypertension. Respirology. 2017;22:157\u201364.","journal-title":"Respirology"},{"key":"816_CR98","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1164\/rccm.201812-2275OC","volume":"200","author":"DE Van der Feen","year":"2019","unstructured":"Van der Feen DE, Kurakula K, Tremblay E, Boucherat O, Bossers GPL, Szulcek R, et al. Multicenter preclinical validation of BET Inhibition for the treatment of pulmonary arterial hypertension. Am J Respir Crit Care Med. 2019;200:910\u201320.","journal-title":"Am J Respir Crit Care Med"},{"key":"816_CR99","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1161\/CIRCRESAHA.115.307004","volume":"117","author":"J Meloche","year":"2015","unstructured":"Meloche J, Potus F, Vaillancourt M, Bourgeois A, Johnson I, Deschamps L, et al. Bromodomain-Containing protein 4: the epigenetic origin of pulmonary arterial hypertension. Circ Res. 2015;117:525\u201335.","journal-title":"Circ Res"},{"key":"816_CR100","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12931-023-02499-y","volume":"24","author":"S Mumby","year":"2023","unstructured":"Mumby S, Perros F, Grynblat J, Manaud G, Papi A, Casolari P, et al. Differential responses of pulmonary vascular cells from PAH patients and controls to TNF\u03b1 and the effect of the BET inhibitor JQ1. Respir Res. 2023;24:193.","journal-title":"Respir Res"},{"key":"816_CR101","doi-asserted-by":"crossref","unstructured":"Chabert C, Khochbin S, Rousseaux S, Veyrenc S, Furze R, Smithers N et al. Inhibition of BET proteins reduces right ventricle hypertrophy and pulmonary hypertension resulting from combined hypoxia and pulmonary inflammation. Int J Mol Sci. 2018;19.","DOI":"10.3390\/ijms19082224"},{"key":"816_CR102","doi-asserted-by":"crossref","unstructured":"Antolic A, Wakimoto H, Jiao Z, Gorham JM, DePalma SR, Lemieux ME, et al. BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. JCI Insight. 2020;5.","DOI":"10.1172\/jci.insight.138687"},{"key":"816_CR103","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.cardfail.2018.07.011","volume":"24","author":"MA Burke","year":"2018","unstructured":"Burke MA, Wakimoto H, Jiao Z, Gorham JM, DePalma SR, Conner DA, et al. Epigenomic control of cardiac fibrosis by bet bromodomain proteins in dilated cardiomyopathy. J Card Fail. 2018;24:S2.","journal-title":"J Card Fail"},{"key":"816_CR104","doi-asserted-by":"publisher","first-page":"490","DOI":"10.4239\/wjd.v10.i10.490","volume":"10","author":"L Athithan","year":"2019","unstructured":"Athithan L, Gulsin GS, McCann GP, Levelt E. Diabetic cardiomyopathy: Pathophysiology, theories and evidence to date. World J Diabetes. 2019;10:490\u2013510.","journal-title":"World J Diabetes"},{"key":"816_CR105","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.taap.2018.05.018","volume":"352","author":"M Guo","year":"2018","unstructured":"Guo M, Wang HX, Chen WJ. BET-inhibition by JQ1 alleviates streptozotocin-induced diabetic cardiomyopathy. Toxicol Appl Pharmacol. 2018;352:9\u201318.","journal-title":"Toxicol Appl Pharmacol"},{"key":"816_CR106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.yjmcc.2020.09.003","volume":"149","author":"J Mu","year":"2020","unstructured":"Mu J, Zhang D, Tian Y, Xie Z, Zou M-h. BRD4 Inhibition by JQ1 prevents high-fat diet-induced diabetic cardiomyopathy by activating PINK1\/Parkin-mediated mitophagy in vivo. J Mol Cell Cardiol. 2020;149:1\u201314.","journal-title":"J Mol Cell Cardiol"},{"key":"816_CR107","first-page":"499","volume":"19","author":"Q Wang","year":"2019","unstructured":"Wang Q, Sun Y, Li T, Liu L, Zhao Y, Li L, et al. Function of BRD4 in the pathogenesis of high glucose\u2013induced cardiac hypertrophy. Mol Med Rep. 2019;19:499\u2013507.","journal-title":"Mol Med Rep"},{"key":"816_CR108","doi-asserted-by":"publisher","first-page":"C457","DOI":"10.1152\/ajpcell.00380.2002","volume":"284","author":"AW Cohen","year":"2003","unstructured":"Cohen AW, Park DS, Woodman SE, Williams TM, Chandra M, Shirani J, et al. Caveolin-1 null mice develop cardiac hypertrophy with hyperactivation of p42\/44 MAP kinase in cardiac fibroblasts. Am J Physiol Cell Physiol. 2003;284:C457\u201374.","journal-title":"Am J Physiol Cell Physiol"},{"key":"816_CR109","doi-asserted-by":"publisher","first-page":"750382","DOI":"10.3389\/fcell.2021.750382","volume":"9","author":"H Zheng","year":"2021","unstructured":"Zheng H, Zhu H, Liu X, Huang X, Huang A, Huang Y. Mitophagy in diabetic cardiomyopathy: roles and mechanisms. Front Cell Dev Biol. 2021;9:750382.","journal-title":"Front Cell Dev Biol"},{"key":"816_CR110","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.carpath.2014.12.002","volume":"24","author":"XH Xi","year":"2015","unstructured":"Xi XH, Wang Y, Li J, Wang FW, Tian GH, Yin MS, et al. Activation of Wnt\/\u03b2-catenin\/GSK3\u03b2 signaling during the development of diabetic cardiomyopathy. Cardiovasc Pathol. 2015;24:179\u201386.","journal-title":"Cardiovasc Pathol"},{"key":"816_CR111","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1016\/j.bbrc.2017.10.027","volume":"493","author":"P Liu","year":"2017","unstructured":"Liu P, Su J, Song X, Wang S. Activation of nuclear \u03b2-catenin\/c-Myc axis promotes oxidative stress injury in streptozotocin-induced diabetic cardiomyopathy. Biochem Biophys Res Commun. 2017;493:1573\u201380.","journal-title":"Biochem Biophys Res Commun"},{"key":"816_CR112","doi-asserted-by":"publisher","first-page":"116387","DOI":"10.1016\/j.bcp.2024.116387","volume":"226","author":"C Huang","year":"2024","unstructured":"Huang C, Liu Z, Chen M, Zhang H, Mo R, Chen R, et al. Up-regulation of BRD4 contributes to gestational diabetes mellitus-induced cardiac hypertrophy in offspring by promoting mitochondria dysfunction in sex-independent manner. Biochem Pharmacol. 2024;226:116387.","journal-title":"Biochem Pharmacol"},{"key":"816_CR113","doi-asserted-by":"publisher","first-page":"107306","DOI":"10.1016\/j.phrs.2024.107306","volume":"207","author":"M Wang","year":"2024","unstructured":"Wang M, Huang Z, Li X, He P, Sun H, Peng Y, et al. Apabetalone, a BET protein inhibitor, inhibits kidney damage in diabetes by preventing pyroptosis via modulating the P300\/H3K27ac\/PLK1 axis. Pharmacol Res. 2024;207:107306.","journal-title":"Pharmacol Res"},{"key":"816_CR114","first-page":"166","volume":"31","author":"M Torres-Fonseca","year":"2019","unstructured":"Torres-Fonseca M, Galan M, Martinez-Lopez D, Ca\u00f1es L, Roldan-Montero R, Alonso J, et al. Pathophisiology of abdominal aortic aneurysm: biomarkers and novel therapeutic targets. Clin Investig Arterioscler. 2019;31:166\u201377.","journal-title":"Clin Investig Arterioscler"},{"key":"816_CR115","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1510\/icvts.2009.208835","volume":"9","author":"H Takagi","year":"2009","unstructured":"Takagi H, Manabe H, Kawai N, Goto SN, Umemoto T. Circulating matrix metalloproteinase-9 concentrations and abdominal aortic aneurysm presence: a meta-analysis. Interact Cardiovasc Thorac Surg. 2009;9:437\u201340.","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"816_CR116","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.trre.2017.08.004","volume":"31","author":"C Sabia","year":"2017","unstructured":"Sabia C, Picascia A, Grimaldi V, Amarelli C, Maiello C, Napoli C. The epigenetic promise to improve prognosis of heart failure and heart transplantation. Transpl Rev (Orlando). 2017;31:249\u201356.","journal-title":"Transpl Rev (Orlando)"},{"key":"816_CR117","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1097\/TP.0000000000003319","volume":"104","author":"J Chen","year":"2020","unstructured":"Chen J, Miao X, Liu C, Liu B, Wu X, Kong D, et al. BET protein Inhibition prolongs cardiac transplant survival via enhanced myocardial autophagy. Transplantation. 2020;104:2317\u201326.","journal-title":"Transplantation"},{"key":"816_CR118","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.1161\/CIRCULATIONAHA.108.842252","volume":"120","author":"C Kassiotis","year":"2009","unstructured":"Kassiotis C, Ballal K, Wellnitz K, Vela D, Gong M, Salazar R, et al. Markers of autophagy are downregulated in failing human heart after mechanical unloading. Circulation. 2009;120:S191\u20137.","journal-title":"Circulation"},{"key":"816_CR119","doi-asserted-by":"publisher","first-page":"101372","DOI":"10.1016\/j.trim.2021.101372","volume":"65","author":"J Lu","year":"2021","unstructured":"Lu J, Liu Y, Wang W, Li P, Qi F. Knockdown of miR-146a in regulatory T cells suppresses heart transplantation rejection in mice by increasing autophagy. Transpl Immunol. 2021;65:101372.","journal-title":"Transpl Immunol"},{"key":"816_CR120","doi-asserted-by":"crossref","unstructured":"Miao X, Jiang Y, Wu Z, Liu H, Gong W. BEZ235 Prolongs murine cardiac allograft survival through the autophagy pathway. Transplant Proc. 2022.","DOI":"10.1016\/j.transproceed.2022.05.025"},{"key":"816_CR121","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/ncb2152","volume":"13","author":"J Kim","year":"2011","unstructured":"Kim J, Kundu M, Viollet B, Guan KL. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol. 2011;13:132\u201341.","journal-title":"Nat Cell Biol"},{"key":"816_CR122","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.cellsig.2019.05.005","volume":"61","author":"M Zhang","year":"2019","unstructured":"Zhang M, Wang B, Urabe G, Huang Y, Plutzky J, Kent KC, et al. The BD2 domain of BRD4 is a determinant in EndoMT and vein graft Neointima formation. Cell Signal. 2019;61:20\u20139.","journal-title":"Cell Signal"},{"key":"816_CR123","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.ebiom.2015.09.045","volume":"2","author":"B Wang","year":"2015","unstructured":"Wang B, Zhang M, Takayama T, Shi X, Roenneburg DA, Kent KC, et al. BET bromodomain Blockade mitigates intimal hyperplasia in rat carotid arteries. EBioMedicine. 2015;2:1650\u201361.","journal-title":"EBioMedicine"},{"key":"816_CR124","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.yjmcc.2018.12.002","volume":"127","author":"S Song","year":"2019","unstructured":"Song S, Liu L, Yu Y, Zhang R, Li Y, Cao W, et al. Inhibition of BRD4 attenuates transverse aortic constriction-and TGF-\u03b2-induced endothelial-mesenchymal transition and cardiac fibrosis. J Mol Cell Cardiol. 2019;127:83\u201396.","journal-title":"J Mol Cell Cardiol"},{"key":"816_CR125","doi-asserted-by":"publisher","first-page":"114190","DOI":"10.1016\/j.bcp.2020.114190","volume":"180","author":"I Norambuena-Soto","year":"2020","unstructured":"Norambuena-Soto I, Ocaranza MP, Cancino-Arenas N, Sanhueza-Olivares F, Villar-Fincheira P, Leiva-Navarrete S, et al. Angiotensin-(1\u20139) prevents vascular remodeling by decreasing vascular smooth muscle cell dedifferentiation through a FoxO1-dependent mechanism. Biochem Pharmacol. 2020;180:114190.","journal-title":"Biochem Pharmacol"},{"key":"816_CR126","doi-asserted-by":"publisher","first-page":"133452","DOI":"10.1016\/j.cej.2021.133452","volume":"431","author":"X Hao","year":"2022","unstructured":"Hao X, Gai W, Ji F, Wang L, Zhao J, Yang F, et al. Biomimetic and responsive nanoparticles loading JQ1 for dual-targeting treatment of vascular restenosis via multiple actions. Chem Eng J. 2022;431:133452.","journal-title":"Chem Eng J"},{"key":"816_CR127","doi-asserted-by":"crossref","unstructured":"Piquereau J, Boet A, P\u00e9choux C, Antigny F, Lambert M, Gressette M, et al. The BET bromodomain inhibitor I-BET-151 induces structural and functional alterations of the heart mitochondria in healthy male mice and rats. Int J Mol Sci. 2019;20.","DOI":"10.3390\/ijms20071527"},{"key":"816_CR128","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1161\/CIRCULATIONAHA.120.047753","volume":"142","author":"A Padmanabhan","year":"2020","unstructured":"Padmanabhan A, Alexanian M, Linares-Saldana R, Gonz\u00e1lez-Ter\u00e1n B, Andreoletti G, Huang Y, et al. BRD4 (Bromodomain-Containing protein 4) interacts with GATA4 (GATA binding protein 4) to govern mitochondrial homeostasis in adult cardiomyocytes. Circulation. 2020;142:2338\u201355.","journal-title":"Circulation"},{"key":"816_CR129","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1161\/CIRCULATIONAHA.120.047239","volume":"142","author":"SY Kim","year":"2020","unstructured":"Kim SY, Zhang X, Schiattarella GG, Altamirano F, Ramos TAR, French KM, et al. Epigenetic reader BRD4 (bromodomain-containing protein 4) governs nucleus-encoded mitochondrial transcriptome to regulate cardiac function. Circulation. 2020;142:2356\u201370.","journal-title":"Circulation"},{"key":"816_CR130","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-20-1707","volume":"26","author":"RR Aggarwal","year":"2020","unstructured":"Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, et al. A phase Ib\/IIa study of the Pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic Castration-resistant prostate cancer. Clin Cancer Res. 2020;26:5338\u201347.","journal-title":"Clin Cancer Res"},{"key":"816_CR131","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41416-020-01180-1","volume":"124","author":"GI Shapiro","year":"2021","unstructured":"Shapiro GI, LoRusso P, Dowlati A, K TD, Jacobson CA, Vaishampayan U, et al. A phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021;124:744\u201353.","journal-title":"Br J Cancer"},{"key":"816_CR132","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ddtec.2016.06.004","volume":"19","author":"G Andrieu","year":"2016","unstructured":"Andrieu G, Belkina AC, Denis GV. Clinical trials for BET inhibitors run ahead of the science. Drug Discov Today Technol. 2016;19:45\u201350.","journal-title":"Drug Discov Today Technol"},{"key":"816_CR133","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ejmech.2018.04.006","volume":"151","author":"Z Liu","year":"2018","unstructured":"Liu Z, Tian B, Chen H, Wang P, Brasier AR, Zhou J. Discovery of potent and selective BRD4 inhibitors capable of blocking TLR3-induced acute airway inflammation. Eur J Med Chem. 2018;151:450\u201361.","journal-title":"Eur J Med Chem"},{"key":"816_CR134","doi-asserted-by":"publisher","first-page":"9070","DOI":"10.1021\/acs.jmedchem.0c00605","volume":"63","author":"A Preston","year":"2020","unstructured":"Preston A, Atkinson S, Bamborough P, Chung CW, Craggs PD, Gordon L, et al. Design and synthesis of a highly selective and in Vivo-Capable inhibitor of the second bromodomain of the bromodomain and extra terminal domain family of proteins. J Med Chem. 2020;63:9070\u201392.","journal-title":"J Med Chem"},{"key":"816_CR135","doi-asserted-by":"crossref","unstructured":"Koravovi\u0107 M, Kova\u010devi\u0107 M, Jovanovi\u0107 M, Tasi\u0107 G, Mayasundari A, Nishiguchi G, et al. Comparative in silico\/in vitro analysis of pharmacokinetic profiles of BET inhibitors. Serb Chem Soc. 2025;90(7\u20138):837\u201356.","DOI":"10.2298\/JSC241211042K"},{"key":"816_CR136","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jare.2023.11.006","volume":"63","author":"J Sun","year":"2024","unstructured":"Sun J, Gui Y, Zhou S, Zheng XL. Unlocking the secrets of aging: epigenetic reader BRD4 as the target to combatting aging-related diseases. J Adv Res. 2024;63:207\u201318.","journal-title":"J Adv Res"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00816-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-025-00816-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-025-00816-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T04:42:35Z","timestamp":1773204155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-025-00816-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":136,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["816"],"URL":"https:\/\/doi.org\/10.1007\/s43440-025-00816-4","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"assertion":[{"value":"6 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}